Clinic for General and Thoracic Surgery, University Clinic of Schleswig-Holstein, Campus Kiel, Arnold-Heller-Str. 3, Haus 18, 24105 Kiel, Germany.
Eur J Surg Oncol. 2011 Sep;37(9):798-804. doi: 10.1016/j.ejso.2011.06.017. Epub 2011 Jul 20.
Some surgical centres consider palliative resection (PR) to be superior to double loop bypass (DLB) as treatment for advanced carcinoma of the pancreatic head. We performed a retrospective study with prospectively collected data at a single centre to compare PR and DLB in regard to quality of life (QoL).
From January 1996 to September 2008, 196 patients were given palliative surgery for advanced pancreatic cancer at the University Hospital of Kiel. Forty-two patients underwent PR and 154 underwent DLB. These groups were compared with regard to survival, post-operative morbidity, and QoL. The EORTC QLQ-C30 was used to assess QoL before surgery, at discharge, three months after surgery, and six months after surgery.
The median survival time after PR was 7.5 months (95% CI: 4.95-10.05) and after DLB was 6 months (95% CI: 4.98-7.02; log rank test: p = 0.066). There were no significant differences in mortality and morbidity rates (7.1% and 45.2% for PR; 3.9% and 38.3% for DLB, respectively). Assessment of QoL indicated that patients who underwent PR had more impairment of some functional metrics and increased symptoms compared to those who underwent DLB.
There was no significant difference in survival or morbidity after PR and DLB, but patients who underwent DLB had better QoL than patients who underwent PR. Therefore, clinicians may want to reconsider the use of PR for patients with advanced pancreatic cancer.
一些外科中心认为姑息性切除术(PR)优于双环旁路术(DLB),是治疗晚期胰头癌的方法。我们在一个中心进行了一项回顾性研究,前瞻性收集数据,比较 PR 和 DLB 在生活质量(QoL)方面的差异。
1996 年 1 月至 2008 年 9 月,基尔大学医院对 196 例晚期胰腺癌患者进行了姑息性手术。42 例患者接受 PR,154 例患者接受 DLB。比较两组患者的生存情况、术后发病率和生活质量。使用 EORTC QLQ-C30 量表在术前、出院时、术后 3 个月和术后 6 个月评估生活质量。
PR 后的中位生存时间为 7.5 个月(95%CI:4.95-10.05),DLB 后的中位生存时间为 6 个月(95%CI:4.98-7.02;log rank 检验:p=0.066)。死亡率和发病率无显著差异(PR 组分别为 7.1%和 45.2%;DLB 组分别为 3.9%和 38.3%)。生活质量评估表明,与 DLB 组相比,PR 组患者某些功能指标受损更严重,症状更多。
PR 和 DLB 后生存或发病率无显著差异,但 DLB 组患者的生活质量优于 PR 组。因此,临床医生可能需要重新考虑对晚期胰腺癌患者使用 PR。